The Department of Breast Medical Oncology at MD Anderson has announced the addition of two new members to its team: Debu Tripathy, M.D., who will serve as the new department chair, and V. Craig Jordan, Ph.D., the developer of a number of proven cancer therapies. The two new recruits will be joining MD Anderson officially this Fall.
One of Jordan’s more popular accomplishments is his part in the discovery of a use for a formerly rejected contraceptive drug (ICI 46,474 – later known as tamoxifen) in treatment for breast cancer. He was also instrumental in developing the use of raloxifene in the treatment of breast cancer. Both medications have been approved by the US Food and Drug Administration for breast cancer prevention. He will be joining Tripathy in October.
Before joining MD Anderson, Tripathy has worked at the Norris Comprehensive Cancer Center at the University of Southern California. He was recently interviewed by Cancer Frontline about his thoughts on mammographies, future breast cancer management, and his future research plans under MD Anderson.
Tripathy shared that he wants to steer the Breast Medical Oncology Department towards a more patient-centered approach. This attitude towards the disease will be in line with the department’s understanding of the uniqueness of each patient and condition, and consequently the need for personalized management and treatment. He envisions the department providing top quality healthcare to Houston and nearby areas, while at the same time be able to contribute on a global scale.
For the full interview with Tripathy, click here.
Another researcher at MD Anderson, Dr. Li Ma, PhD, has been devoting her efforts to developing new ways to battle breast cancer by studying breast cancer cell resistance to radiation.